Value of PCA3 to Predict Biopsy Outcome and Its Potential Role in Selecting Patients for Multiparametric MRI
Open Access
- 28 May 2013
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 14 (6), 11347-11355
- https://doi.org/10.3390/ijms140611347
Abstract
PCA3 (prostate cancer gene 3) and multiparametric 3 tesla MRI are new promising diagnostic tools in the detection of PCa. Our aim was to study the clinical value of the Progensa PCA3-test: its predictive value for biopsy outcome, Gleason score and MRI outcome. We evaluated, retrospectively, 591 patients who underwent a Progensa PCA3-test at the Radboud University Nijmegen Medical Centre between May 2006 and December 2009. Prostate biopsies were performed in 290 patients; a multiparametric 3 tesla MRI of the prostate was performed in 163/591 patients. The PCA3-score was correlated to biopsy results and MRI outcome. The results show that PCA3 was highly predictive for biopsy outcome (p < 0.001); there was no correlation with the Gleason score upon biopsy (p = 0.194). The PCA3-score of patients with a suspicious region for PCa on MRI was significantly higher (p < 0.001) than in patients with no suspicious region on MRI (52 vs. 21). In conclusion, PCA3 is a valuable diagnostic biomarker for PCa; it did not correlate with the Gleason score. Furthermore, multiparametric MRI outcome was significantly correlated with the PCA3-score. Thus, PCA3 could be used to select patients that require MRI. However, in patients with a negative PCA3 and high clinical suspicion of PCa, a multiparametric MRI should also be done.This publication has 21 references indexed in Scilit:
- Clinical Evaluation of the PCA3 Assay in Guiding Initial Biopsy DecisionsJournal of Urology, 2011
- International epidemiology of prostate cancer: Geographical distribution and secular trendsMolecular Nutrition & Food Research, 2009
- Clinical Utility of the PCA3 Urine Assay in European Men Scheduled for Repeat BiopsyEuropean Urology, 2008
- PCA3: A Molecular Urine Assay for Predicting Prostate Biopsy OutcomeJournal of Urology, 2008
- Prostate Cancer: Body-Array versus Endorectal Coil MR Imaging at 3 T—Comparison of Image Quality, Localization, and Staging PerformanceRadiology, 2007
- PCA3 Molecular Urine Assay for Prostate Cancer in Men Undergoing Repeat BiopsyUrology, 2007
- Standardized Threshold Approach Using Three-Dimensional Proton Magnetic Resonance Spectroscopic Imaging in Prostate Cancer Localization of the Entire ProstateInvestigative Radiology, 2007
- APTIMA PCA3 Molecular Urine Test: Development of a Method to Aid in the Diagnosis of Prostate CancerClinical Chemistry, 2006
- Use of Prostate-Specific Antigen (PSA) Isoforms for the Detection of Prostate Cancer in Men with a PSA Level of 2–10 ng/ml: Systematic Review and Meta-AnalysisEuropean Urology, 2005
- DD3: a new prostate-specific gene, highly overexpressed in prostate cancer.1999